ArticleCell2018
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 428 papers.
0numbers the graph read from it
0cells of the map it votes in
428citing papers in PubMed
58.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
428 citing papers in PubMed, 734 citations in OpenAlex.
- Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.Cell reports. Medicine · 2025Trial
- Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.Cell reports. Medicine · 2025Trial
- AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.Nature communications · 2024Trial
- A novel multiplex digital PCR assay for simultaneous quantification of androgen receptor amplification, mutations, and splice variants in cell-free nucleic acids from metastatic castration-resistant prostate cancer.The journal of liquid biopsy · 2026Article
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.Nature communications · 2026Article
- Prioritizing context-specific genetic risk mechanisms in 11 solid cancers.Journal of the National Cancer Institute · 2026Article
- Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026Article
- Androgen receptor drives divergent chromatin accessibility programs in benign and malignant prostate epithelial cells.Nucleic acids research · 2026Article
- The RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals.bioRxiv : the preprint server for biology · 2026Article
- Glutamine synthesis pathway promotes the survival and recurrence of dormant tumor cells in prostate cancer.Cell death discovery · 2026Article
- Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026Review
- ADT and activation of HGF and WNT axes in double-null prostate cancer.Nature reviews. Urology · 2026Review
- Transcriptome-wide association studies implicate RCC1 and PHACTR4 in prostate cancer survival.European journal of human genetics : EJHG · 2026Article
- CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment.Journal for immunotherapy of cancer · 2026Article
- Pipettes and Pipelines: The Weapons of Omics Sciences for a New Age of Clinical Studies.Current issues in molecular biology · 2026Review
- PHLPP is neither a Phosphatase nor a Tumor Suppressor.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.JCO precision oncology · 2026Article
- Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Single-Cell Analysis Reveals Pre-Existing Basal-Associated Epithelial States in Metastatic Hormone-Naïve Prostate Cancer.International journal of molecular sciences · 2026Article
368 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
63 authors at 19 institutions in 2 countries.
David A QuigleyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA; Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA.
Ha X DangMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA; Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Shuang G ZhaoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Paul LloydDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Rahul AggarwalDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
Adam FoyeDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Vishal KothariDepartment of Radiation Oncology, UCSF, San Francisco, CA, USA.
Marc D PerryDepartment of Radiation Oncology, UCSF, San Francisco, CA, USA.
Adina M BaileyDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Denise PlaydleDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Travis J BarnardDepartment of Radiation Oncology, UCSF, San Francisco, CA, USA.
Li ZhangDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Jin ZhangCancer Biology Division, Department of Radiation Oncology, Washington University in St. Louis, MO USA; Institute for Informatics (I(2)), Washington University in St. Louis, MO.
Jack F YoungrenDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Marcin P CieslikDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Abhijit ParoliaDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
George ThomasKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Department of Pathology, Oregon Health and Science University, Portland, OR, USA.
Kim N ChiVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada.
Martin GleaveVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Nathan A LackVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Amina ZoubeidiVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Robert E ReiterJonsson Comprehensive Cancer Center, Department of Urology, UCLA, Los Angeles, CA, USA; VA Greater Los Angeles Healthcare System, Department of Medicine, Los Angeles, CA, USA.
Matthew B RettigJonsson Comprehensive Cancer Center, Department of Urology, UCLA, Los Angeles, CA, USA.
Owen WitteDepartment of Microbiology, Immunology, and Molecular Genetics at the David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Charles J RyanDivision of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Lawrence FongDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Won KimDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Terence FriedlanderDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Jonathan ChouDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Haolong LiDepartment of Radiation Oncology, UCSF, San Francisco, CA, USA.
Rajdeep DasDepartment of Radiation Oncology, UCSF, San Francisco, CA, USA.
Hui LiDepartment of Radiation Oncology, UCSF, San Francisco, CA, USA.
Ruhollah Moussavi-BaygiDepartment of Radiation Oncology, UCSF, San Francisco, CA, USA.
Hani GoodarziDepartment of Biophysics and Biochemistry, UCSF, San Francisco, CA, USA; Department of Urology, UCSF, San Francisco, CA, USA.
Luke A GilbertHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA; Department of Urology, UCSF, San Francisco, CA, USA.
Primo N LaraDivision of Hematology Oncology, Department of Internal Medicine, University of California Davis, Sacramento, CA, USA; Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Christopher P EvansComprehensive Cancer Center, University of California Davis, Sacramento, CA, USA; Department of Urologic Surgery, University of California Davis, Sacramento, CA, USA.
Theodore C GoldsteinDivision of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA; UC Sant Cruz Genome Institute and Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, USA.
Joshua M StuartUC Sant Cruz Genome Institute and Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, USA.
Scott A TomlinsDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Daniel E SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
R Keira CheethamIllumina, Inc., San Diego, CA, USA.
Donavan T ChengIllumina, Inc., San Diego, CA, USA.
Kyle FarhIllumina, Inc., San Diego, CA, USA.
Julian S GehringIllumina, Inc., San Diego, CA, USA.
Jörg HakenbergIllumina, Inc., San Diego, CA, USA.
Arnold LiaoIllumina, Inc., San Diego, CA, USA.
Philip G FebboIllumina, Inc., San Diego, CA, USA.
John ShonIllumina, Inc., San Diego, CA, USA.
Brad SicklerIllumina, Inc., San Diego, CA, USA.
Serafim BatzoglouIllumina, Inc., San Diego, CA, USA.
Karen E KnudsenDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Housheng H HePrincess Margaret Cancer Centre/University Health Network, Toronto, ON, Canada.
Jiaoti HuangDepartment of Pathology, Duke University, Durham, NC, USA.
Alexander W WyattVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA; Division of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Ann Arbor, MI, USA; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA; Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Urology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: arul@med.umich.edu.
Christopher A MaherMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA; Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: christophermaher@wustl.edu.
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA; Division of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA. Electronic address: eric.small@ucsf.edu.
Felix Y FengHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA; Division of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA; Department of Radiation Oncology, UCSF, San Francisco, CA, USA; Department of Urology, UCSF, San Francisco, CA, USA. Electronic address: felix.feng@ucsf.edu.
University of California, San Francisco · USIllumina (United States) · USUniversity of British Columbia · CAMichigan Center for Translational Pathology · USOregon Health & Science University · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Michigan · USUniversity of California, Davis · USUniversity of Minnesota · USWashington University in St. Louis · USBC Cancer Agency · CADuke University · USJames S. McDonnell Foundation · USPrincess Margaret Cancer Centre · CAThomas Jefferson University · USUCLA Jonsson Comprehensive Cancer CenterUniversity of California, Los Angeles · USUniversity of California, Santa Cruz · USVA Greater Los Angeles Healthcare System · US
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1MTissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6MMolecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MAR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9MDiscovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancerU01CA214170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2016 to 2021
$3.3MA functional genomics approach to determine the mechanism of cellular response to new anti-cancer R00CA204602 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GILBERT, LUKE · 2017 to 2019
$747kSWI/SNF chromatin remodelers in tumor-associated antigen-specific CD8+ cytotoxic T cellsK00CA245825 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAROLIA, ABHIJIT · 2021 to 2024
$388kExploring mechanisms of transcriptional and chromatin dysregulation in cancerF99CA245825 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAROLIA, ABHIJIT · 2019 to 2020
$76kHoward Hughes Medical InstituteNCI NIH HHS F99 CA245825NCI NIH HHS K00 CA245825NCI NIH HHS P30 CA082103NCI NIH HHS P50 CA097186NCI NIH HHS P50 CA186786NCI NIH HHS R00 CA204602NCI NIH HHS R01 CA174777NCI NIH HHS T32 CA108462NCI NIH HHS U01 CA214170
Abstract
While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor/38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kb upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
Indexed as
AgedAged, 80 and overBRCA2 ProteinCyclin-Dependent KinasesDNA Copy Number VariationsExomeGene Expression ProfilingGenomicsGenomic Structural VariationHumansMaleMiddle AgedMutationNeoplasm MetastasisProstatic NeoplasmsProto-Oncogene Proteins c-mycAR protein, humanBRCA2 ProteinBRCA2 protein, humanCDK12 protein, humanCyclin-Dependent KinasesMYC protein, humanProto-Oncogene Proteins c-mycReceptors, AndrogenTP53 protein, humanTumor Suppressor Protein p53androgen receptorBRCA2castration resistant prostate cancerchromothripsisgene fusiongenomicsmetastasesstructural variationtandem duplicationwhole-genome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.